Peripheral Nerve Injuries Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals

The Key Peripheral Nerve Injuries Companies in the market include - Axogen Corporation, Toyobo, KLISBio, Orthocell Limited, Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others.

DelveInsight's "Peripheral Nerve Injuries Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Peripheral Nerve Injuries, historical and forecasted epidemiology as well as the Peripheral Nerve Injuries market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Peripheral Nerve Injuries market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peripheral Nerve Injuries Market Forecast [https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Peripheral Nerve Injuries Market Report:

*
The Peripheral Nerve Injuries market size was valued approximately USD 2.4 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In May 2025, A pioneering first-in-human study demonstrated the promise of the PeriPulse Registered Nerve Stimulation System-a wearable, temporary nerve stimulator-in delivering electrical stimulation therapy to support the regeneration of acutely injured peripheral nerves. Published in Bioelectronic Medicine, the study reported that 87.5% of patients receiving the treatment showed clinically meaningful improvements in sensation six months post-injury, compared to pre-surgery status. These findings suggest electrical stimulation may play a vital role in promoting functional nerve recovery. Peripheral nerve injury treatment remains a significant challenge, particularly in acute trauma, as surgery alone often leads to delayed and incomplete recovery, placing strain on patients and healthcare systems alike.

*
In April 2025, TISSIUM, a privately held medtech company specializing in biomorphic programmable polymers for tissue reconstruction, announced clinical data presented at the IFSSH Congress in Washington, D.C. on March 27, 2025. The findings highlight the promise of its COAPTIUM Registered CONNECT System-an innovative, sutureless, and atraumatic approach for peripheral nerve repair. Peripheral nerve injuries continue to present a serious clinical challenge, often leading to compromised nerve function, diminished dexterity, and a decline in overall quality of life.

*
In September 2024, Neuraptive Therapeutics Inc., a biopharmaceutical company specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline findings from its ongoing Phase 2 NEUROFUSE Study will be shared at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting.

*
In January 2024, The U.S. Food and Drug Administration (FDA) has recognized Neuraptive Therapeutics' NTX-001 as a promising treatment for peripheral nerve injury. It first granted the therapy Fast Track Designation in May 2020, and subsequently awarded it Orphan Drug Designation.

*
In 2023, the United States represented the largest market for peripheral nerve injury treatments within the 7MM, reaching a value of approximately USD 1.5 billion.

*
The US had the highest prevalence of peripheral nerve injuries within the 7MM in 2023, with case numbers approaching 1.7 million.

*
Within the EU4 (Germany, France, Italy, Spain) and the UK, Italy had the most peripheral nerve injury cases, with France second highest, and Spain reporting the fewest.

*
In 2023, the United States saw a greater incidence of upper limb injuries, with nearly 1.2 million cases, compared to roughly 0.5 million cases of lower limb injuries.

*
The United States led the 7MM in surgical procedures for peripheral nerve injuries in 2023, with approximately 770,000 surgeries performed.

*
Key Peripheral Nerve Injuries Companies: Axogen Corporation, Toyobo, KLISBio, Orthocell Limited, Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others

*
Key Peripheral Nerve Injuries Therapies: Avance Nerve Graft, Nerbridge, SilkBridge, CelGro, Remplir, NTX-001, CAPNP, QUTENZA, and others

*
The Peripheral Nerve Injuries epidemiology based on extremities-specific population analyzed that the epidemiological model estimates a higher proportion of upper extremities in Peripheral Nerve Injuries

*
The Peripheral Nerve Injuries market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Peripheral Nerve Injuries pipeline products will significantly revolutionize the Peripheral Nerve Injuries market dynamics.

Peripheral Nerve Injuries Overview

The central nervous system-the brain and spinal cord-transmits information to every other organ of the body through the enormous communications network known as the peripheral nervous system (PNS). The brain and spinal cord are also provided with sensory information through peripheral nerves (PN), such as a message indicating that the feet are cold or a finger is burned.

Get a Free sample for the Peripheral Nerve Injuries Market Report

https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market [https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Peripheral Nerve Injuries Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Peripheral Nerve Injuries Epidemiology Segmentation:

The Peripheral Nerve Injuries market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Peripheral Nerve Injuries

*
Prevalent Cases of Peripheral Nerve Injuries by severity

*
Gender-specific Prevalence of Peripheral Nerve Injuries

*
Diagnosed Cases of Episodic and Chronic Peripheral Nerve Injuries

Download the report to understand which factors are driving Peripheral Nerve Injuries epidemiology trends @ Peripheral Nerve Injuries Epidemiology Forecast [https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Peripheral Nerve Injuries Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Nerve Injuries market or expected to get launched during the study period. The analysis covers Peripheral Nerve Injuries market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Peripheral Nerve Injuries Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Peripheral Nerve Injuries Therapies and Key Companies

*
Avance Nerve Graft: Axogen Corporation

*
Nerbridge: Toyobo

*
SilkBridge: KLISBio

*
CelGro: Orthocell Limited

*
Remplir: Orthocell

*
NTX-001: Neuraptive Therapeutics

*
CAPNP: Samyang Biopharmaceuticals

*
QUTENZA: Astellas Pharma Inc

Discover more about therapies set to grab major Peripheral Nerve Injuries market share @ Peripheral Nerve Injuries Treatment Market [https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Peripheral Nerve Injuries Market Drivers

*
High incidence of nerve injuries

*
Availability of technologically advanced nerve repair and regeneration products

*
Research and Development

Peripheral Nerve Injuries Market Barriers

*
Delayed and under diagnosis

*
Lack of epidemiological studies

*
Limited understanding of the pathophysiology of Peripheral Nerve Injuries and repair

*
Lack of approved therapies and weak clinical pipeline

Scope of the Peripheral Nerve Injuries Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Peripheral Nerve Injuries Companies: Axogen Corporation, Toyobo, KLISBio, Orthocell Limited, Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others

*
Key Peripheral Nerve Injuries Therapies: Avance Nerve Graft, Nerbridge, SilkBridge, CelGro, Remplir, NTX-001, CAPNP, QUTENZA, and others

*
Peripheral Nerve Injuries Therapeutic Assessment: Peripheral Nerve Injuries current marketed and Peripheral Nerve Injuries emerging therapies

*
Peripheral Nerve Injuries Market Dynamics: Peripheral Nerve Injuries market drivers and Peripheral Nerve Injuries market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Peripheral Nerve Injuries Unmet Needs, KOL's views, Analyst's views, Peripheral Nerve Injuries Market Access and Reimbursement

To know more about Peripheral Nerve Injuries companies working in the treatment market, visit @ Peripheral Nerve Injuries Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Peripheral Nerve Injuries Market Report Introduction

2. Executive Summary for Peripheral Nerve Injuries

3. SWOT analysis of Peripheral Nerve Injuries

4. Peripheral Nerve Injuries Patient Share (%) Overview at a Glance

5. Peripheral Nerve Injuries Market Overview at a Glance

6. Peripheral Nerve Injuries Disease Background and Overview

7. Peripheral Nerve Injuries Epidemiology and Patient Population

8. Country-Specific Patient Population of Peripheral Nerve Injuries

9. Peripheral Nerve Injuries Current Treatment and Medical Practices

10. Peripheral Nerve Injuries Unmet Needs

11. Peripheral Nerve Injuries Emerging Therapies

12. Peripheral Nerve Injuries Market Outlook

13. Country-Wise Peripheral Nerve Injuries Market Analysis (2020-2034)

14. Peripheral Nerve Injuries Market Access and Reimbursement of Therapies

15. Peripheral Nerve Injuries Market Drivers

16. Peripheral Nerve Injuries Market Barriers

17. Peripheral Nerve Injuries Appendix

18. Peripheral Nerve Injuries Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peripheral-nerve-injuries-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-orthocell-neuraptive-therapeutics-samyang-biopharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.